• Jeffrey E Olgin, Mark J Pletcher, Eric Vittinghoff, Jerzy Wranicz, Rajesh Malik, Daniel P Morin, Steven Zweibel, Alfred E Buxton, Claude S Elayi, Eugene H Chung, Eric Rashba, Martin Borggrefe, Trisha F Hue, Carol Maguire, Feng Lin, Joel A Simon, Stephen Hulley, Byron K Lee, and VEST Investigators.
• From the Division of Cardiology, Department of Medicine, the UCSF Center for the Prevention of Sudden Death (J.E.O., C.M., B.K.L.) and the Department of Epidemiology and Biostatistics (M.J.P., E.V., T.F.H., F.L., J.A.S., S.H.), University of California, San Francisco, San Francisco; the Department of Electrocardiology, Medical University of Lodz, Lodz, Poland (J.W.); McLeod Regional Medical Center, Florence, SC (R.M.); Ochsner Medical Center and Ochsner Clinical School, University of Queensland School of Medicine, New Orleans (D.P.M.); Hartford Healthcare Heart and Vascular Institute and University of Connecticut School of Medicine, Hartford (S.Z.); Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (A.E.B.); Gill Heart Institute, University of Kentucky, and Veterans Affairs Medical Center, Lexington (C.S.E.); the Department of Internal Medicine, University of Michigan, Michigan Medicine, Ann Arbor (E.H.C.); Stony Brook Medicine, Stony Brook, NY (E.R.); and First Department of Medicine-Cardiology, University Medical Center Mannheim, Mannheim, and DZHK (German Center for Cardiovascular Research), Heidelberg - both in Germany (M.B.).
• N. Engl. J. Med. 2018 Sep 27; 379 (13): 1205-1215.

BackgroundDespite the high rate of sudden death after myocardial infarction among patients with a low ejection fraction, implantable cardioverter-defibrillators are contraindicated until 40 to 90 days after myocardial infarction. Whether a wearable cardioverter-defibrillator would reduce the incidence of sudden death during this high-risk period is unclear.MethodsWe randomly assigned (in a 2:1 ratio) patients with acute myocardial infarction and an ejection fraction of 35% or less to receive a wearable cardioverter-defibrillator plus guideline-directed therapy (the device group) or to receive only guideline-directed therapy (the control group). The primary outcome was the composite of sudden death or death from ventricular tachyarrhythmia at 90 days (arrhythmic death). Secondary outcomes included death from any cause and nonarrhythmic death.ResultsOf 2302 participants, 1524 were randomly assigned to the device group and 778 to the control group. Participants in the device group wore the device for a median of 18.0 hours per day (interquartile range, 3.8 to 22.7). Arrhythmic death occurred in 1.6% of the participants in the device group and in 2.4% of those in the control group (relative risk, 0.67; 95% confidence interval [CI], 0.37 to 1.21; P=0.18). Death from any cause occurred in 3.1% of the participants in the device group and in 4.9% of those in the control group (relative risk, 0.64; 95% CI, 0.43 to 0.98; uncorrected P=0.04), and nonarrhythmic death in 1.4% and 2.2%, respectively (relative risk, 0.63; 95% CI, 0.33 to 1.19; uncorrected P=0.15). Of the 48 participants in the device group who died, 12 were wearing the device at the time of death. A total of 20 participants in the device group (1.3%) received an appropriate shock, and 9 (0.6%) received an inappropriate shock.ConclusionsAmong patients with a recent myocardial infarction and an ejection fraction of 35% or less, the wearable cardioverter-defibrillator did not lead to a significantly lower rate of the primary outcome of arrhythmic death than control. (Funded by the National Institutes of Health and Zoll Medical; VEST ClinicalTrials.gov number, NCT01446965 .).

23 keywords...

hide…